The aim of this clinical trial is to determine the efficacy of tocilizumab (an IL-6 inhibitor) in treatment-refractory chronic inflammatory forms of CPPD.
The main questions this trial aims to answer are:
* Can tocilizumab improve joint pain in patients with chronic inflammatory CPPD disease?
* Does tocilizumab improve quality of life in patients with chronic inflammatory CPPD disease?
Participants will receive a monthly infusion of tocilizumab or placebo for three months.